On March 17, 2014 (U.S. time), French pharmaceutical company Pierre Fabre announced the FDA approval of Hemangeol (propranolol hydrochloride), the first and only FDA-approved treatment for hemangiomas in infants and children. Propranolol (English name: propranolol , Chinese trade name: Xindean) is an old classic drug for the treatment of heart disease, especially coronary heart disease, which was put into clinical use in the 1960s. Its inventor, British scientist Sir James W. Black, was awarded the 1988 Nobel Prize in Physiology or Medicine for it. Since the New England Journal of Medicine introduced the successful use of Xanax in the treatment of hemangioma in 2008, Xanax has provided a new method for the effective treatment of infantile hemangioma (infantile hemangioma), with remarkable efficacy and little adverse reaction, which has brought a blessing to the majority of hemangioma children, and also provided a new way of thinking in the basic research of hemangioma. The treatment originated from the serendipitous discovery of Dr. Léauté-Labrèze and other doctors at Bordeaux Children’s Hospital in France, and the earliest report was published in the world’s authoritative medical journal New England Journal of Medicine (NEJM) in June 2008, and also released at the congress of the International Society for the Study of Hemangiomas and Vascular Diseases (ISSVA) held in Boston. (ISSVA) Congress in Boston, arguably one of the most significant discoveries in the history of hemangioma treatment. On February 19, 2015, the world’s leading medical journal, the New England Journal of Medicine, NEJM, republished a full-text paper on the largest clinical trial to date of hemangiomas in infants and young children, conducted at 56 hospitals in 16 countries around the world, by Léauté-Labrèze et al. at the Children’s Hospital of Bordeaux, France, where the authors used propranolol to treat up to 456 children. The authors used propranolol to treat up to 456 children, and found that oral treatment with propranolol hydrochloride at 3 mg/kg/d for 6 months was significantly more effective than 1 mg/kg/d, and that after more than a year of clinical follow-up, the children did not lose weight, have cardiorespiratory abnormalities, or neurologic developmental disorders. The emergence of intestinal symptoms such as constipation and sleep disorders were short-term adverse reactions.